Skip to main content

Ironwood Pharmaceuticals, Inc.

corporate_fare Company Profile

Ironwood Pharmaceuticals, Inc.

IRWD·NASDAQ·Life Sciences·CIK 0001446847

Our Company is a biotechnology company that develops and sells therapies for people with gastrointestinal (GI) and rare diseases. We focus on creating and commercializing innovative products in areas where there is a significant unmet medical need, using our expertise in GI and rare diseases. Our commercial product, LINZESS® (linaclotide), is the first U.S. FDA-approved guanylate cyclase type C (GC-C) agonist. In the U.S., LINZESS is indicated for irritable bowel syndrome with constipation (IBS-C) in adults and pediatric patients 7 years of age and older, chronic idiopathic constipation (CIC) in adults, and functional constipation (FC) in pediatric patients ages 6-17 years-old. LINZESS is also available for adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is sold as CONSTELLA® in Canada for adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC, and to adults with IBS-C in certain European countries. We have strategic partnerships with pharmaceutical companies to develop and commercialize linaclotide globally, including with AbbVie Inc. in the U.S. and all countries worldwide except China (including Hong Kong and Macau) and Japan, AstraZeneca AB in China (including Hong Kong and Macau), and Astellas Pharma Inc. in Japan. Following our acquisition of VectivBio Holding AG in June 2023, we are developing apraglutide, a next-generation, synthetic long-acting peptide analog of glucagon-like peptide-2 (GLP-2), for short bowel syndrome (SBS) patients who rely on parenteral support (PS).

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 23 items for IRWD at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 9 rated 8 or above. Recent SEC coverage for IRWD spans 10-Q, 8-K, DEFA14A, DEF 14A.

Recent high-impact activity:

  • Ironwood 10-Q Corrects Q3 Operating Cash Flow to $67.4M From $130.8M
  • Ironwood Beats Q3 Estimates, Lifts 2026 Revenue and EBITDA Outlook
  • Ironwood Lifts 2026 Guidance Again as Q3 Revenue Reaches $133M and Adjusted EBITDA Hits $98M
  • Ironwood Posts 36c Adjusted EPS for Third Quarter
  • Ironwood Names Tammi Gaskins CEO; McCourt Retires After 17 Years

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$296.15M
Net Income
$24.02M
Diluted EPS
$0.15
Op. Cash Flow
$127.04M
Free Cash Flow
$127.01M
Operating Income
$98.5M
Cash & Equivalents
$215.46M
Debt / Equity
0.00×
Net Margin
8.1%
Shares Outstanding
163.06M sh
Source: 10-K · filed 2026-02-26 · accession 0001104659-26-020489

Short Interest & Short Volume

9.84 days to cover

FINRA reported short interest of 14,860,120 shares in IRWD as of the October 30, 2026 settlement, a 6.5% decrease from the prior period — about 9.8 days to cover at its recent average daily volume. On November 20, 2026, 43.1% of IRWD volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)14,860,120 shares as of October 30, 2026
Change vs prior period▼ 6.5%
Days to cover9.84 at avg daily volume of 1,509,777
Daily short volume (FINRA facilities)43.1% of 1,027,236 shares on November 20, 2026
5-day average short volume46.0%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with I →
$4.6 -2.13% today
52-week range · as of 2026-11-05 $1.88 – $5.78
Market cap
$778.09M
Volume
3M (1.3× avg)
3-mo avg 2.4M
Live data · 2026-11-22 12:42 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed IRWD - Latest Insights

IRWD
Nov 05, 2026, 4:06 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $4.04
Real-time Price: $4.60 info
Change: +$0.560 (+14%) info
Market Cap: $778.089M info
IRWD
Nov 05, 2026, 7:54 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $4.14
Real-time Price: $4.60 info
Change: +$0.465 (+11%) info
Market Cap: $778.089M info
IRWD
Nov 05, 2026, 7:05 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.25
Real-time Price: $4.60 info
Change: +$0.350 (+8%) info
Market Cap: $778.089M info
IRWD
Nov 05, 2026, 7:05 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $3.78
Real-time Price: $4.60 info
Change: +$0.820 (+22%) info
Market Cap: $778.089M info
IRWD
Oct 16, 2026, 7:30 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.78
Real-time Price: $4.60 info
Change: +$0.820 (+22%) info
Market Cap: $778.089M info
IRWD
Oct 16, 2026, 7:30 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $3.78
Real-time Price: $4.60 info
Change: +$0.820 (+22%) info
Market Cap: $778.089M info
IRWD
Aug 06, 2026, 4:07 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $4.26
Real-time Price: $4.60 info
Change: +$0.340 (+8%) info
Market Cap: $778.089M info
IRWD
Aug 06, 2026, 7:19 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $4.02
Real-time Price: $4.60 info
Change: +$0.580 (+14%) info
Market Cap: $778.089M info
IRWD
Aug 06, 2026, 7:12 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.27
Real-time Price: $4.60 info
Change: +$0.330 (+8%) info
Market Cap: $778.089M info
IRWD
Jun 18, 2026, 4:14 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.54
Real-time Price: $4.60 info
Change: +$1.06 (+30%) info
Market Cap: $778.089M info
IRWD
Jun 15, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.69
Real-time Price: $4.60 info
Change: +$0.910 (+25%) info
Market Cap: $778.089M info
IRWD
May 29, 2026, 10:54 AM EDT
Source: dpa-AFX
Importance Score:
8
Price at Filing: $3.55
Real-time Price: $4.60 info
Change: +$1.05 (+30%) info
Market Cap: $778.089M info
IRWD
May 13, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.05
Real-time Price: $4.60 info
Change: +$0.550 (+14%) info
Market Cap: $778.089M info
IRWD
May 07, 2026, 4:08 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $4.32
Real-time Price: $4.60 info
Change: +$0.280 (+6%) info
Market Cap: $778.089M info
IRWD
May 07, 2026, 7:10 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $5.15
Real-time Price: $4.60 info
Change: -$0.550 (-11%) info
Market Cap: $778.089M info
IRWD
May 07, 2026, 7:05 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $4.89
Real-time Price: $4.60 info
Change: -$0.290 (-6%) info
Market Cap: $778.089M info
IRWD
Apr 28, 2026, 4:09 PM EDT
Filing Type: DEFA14A
Importance Score:
7
Price at Filing: $4.23
Real-time Price: $4.60 info
Change: +$0.3708 (+9%) info
Market Cap: $778.089M info
IRWD
Apr 28, 2026, 4:06 PM EDT
Filing Type: DEF 14A
Importance Score:
9
Price at Filing: $4.22
Real-time Price: $4.60 info
Change: +$0.3809 (+9%) info
Market Cap: $778.089M info
IRWD
Mar 19, 2026, 6:35 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $3.27
Real-time Price: $4.60 info
Change: +$1.33 (+41%) info
Market Cap: $778.089M info
IRWD
Mar 17, 2026, 8:34 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $3.23
Real-time Price: $4.60 info
Change: +$1.37 (+42%) info
Market Cap: $778.089M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets